Skip to main content
Premium Trial:

Request an Annual Quote

AMP Submits Proposal to AMA Covering CPT Codes for Sequencing-based Assays

NEW YORK (GenomeWeb News) – The Association for Molecular Pathology today announced that it has submitted to an American Medical Association panel its proposal for CPT codes for sequencing-based assays.

The proposal was developed by AMP's Economic Affairs Committee — which develops and advocates for sound economic policies that "promote the provision of high quality molecular pathology services" — and was submitted to AMA's CPT Editorial Panel.

As capabilities in human genome analysis increase, AMP said that countless new reimbursement codes will be required. Its report to AMA comprises two approaches: a technology-agnostic, single-code strategy; and a code-mate strategy.

The first method would rely "on a single, methodology-agnostic code that includes both technical and interpretive work," while the latter approach would introduce separate codes for technical processes and for interpretive processes.

Today's report follows a white paper from AMP in 2011 for CPT coding of molecular pathology tests, the association said. Last May, GenomeWeb Daily News sister publication Clinical Sequencing News also reported that AMP was creating a proposal for CPT coding of next-generation sequencing-based assays.

The full AMP proposal can be viewed here.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.